Topstone Research Selects OmniComm’s TrialMaster EDC
Fort Lauderdale, FL, April 20, 2018 (GLOBE NEWSWIRE) -- Topstone Research, a full-service, contract research organization (CRO), has signed a new agreement with OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of clinical data management technology. Under the agreement, Topstone will use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple Topstone research sites.
“We chose OmniComm because Topstone’s growing Data Management department is at a stage where we need to be better equipped to handle more complex trials, with a flexible and customizable EDC system,” said Muhammad Bilal, senior director-Clinical Data Management and Biostatistics at Topstone.
OmniComm was selected as one of Topstone preferred EDC systems based on TrialMaster’s inherent flexibility and broad capabilities to support clinical studies across all phases of clinical development. Deploying studies in an efficient, timely and cost-effective manner was especially important to Topstone. OmniComm’s robust, state-of-the art, compliant hosting environment was another critical factor in the selection process.
“OmniComm continues to make significant progress in the CRO market due to the speed of setup and our comprehensive suite of very robust tools,” said Kuno van der Post, Ph.D., chief commercial officer, OmniComm Systems. “We are thrilled that Topstone has selected TrialMaster to be deployed across a full spectrum of trial phases.”
About Topstone Research
Topstone Research is a specialty CRO with an unwavering commitment to quality and service flexibility. Topstone’s clinical professionals bring essential expertise to help biopharmaceutical organizations successfully solve today’s challenges in clinical research. In addition to offering a full selection of clinical trial management services, Topstone provides an unmatched and exceptional experience, from the first point of contact to final delivery. Please visit www.topstoneresearch.com for more information.
About OmniComm Systems, Inc.
OmniComm Systems provides a role in enhancing patient lives by shortening time to market of essential life-saving treatments. OmniComm Systems is dedicated to providing the latest eClinical technology enabling the world’s life science organizations to maximize the value of their clinical research investments. OmniComm’s solutions provide better trial oversight and study delivery, connecting patients to better healthcare. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com for more information.
Trademarks
OmniComm, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info
Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
KvanderPost@omnicomm.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
